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Background: Antimicrobial surveillance is important for providing an up-to-date understanding of the epidemiology of antimi-
crobial resistance and for creating a forum for rational drug development. In this study, we analyzed antimicrobial test data gen-
erated in 2011 by hospitals and commercial laboratories participating in the Korean Nationwide Surveillance of Antimicrobial 
Resistance program (KONSAR).
Materials and Methods: Data on the results of susceptibility tests conducted in 32 hospitals and two commercial laboratories 
were analyzed. Data on isolates from patients admitted to an intensive care unit (ICU) and those admitted to other wards were 
compared. Intermediate susceptibility was not analyzed and duplicate isolates were excluded.
Results: Escherichia coli was the most prevalent organism identified in both the hospital and commercial laboratories. Among 
the hospital isolates, methicillin-resistant Staphylococcus aureus (MRSA), penicillin G-non-susceptible Streptococcus pneu-
moniae, and ampicillin-resistant Enterococcus faecium remained as prevalent as they were in 2009. The proportion of van-
comycin-resistant E. faecium (VR-EFM) slightly decreased from 29% in 2009 to 23% in 2011. Resistance rates of Klebsiella 
pneumoniae to ceftazidime, cefoxitin, fluoroquinolone, and amikacin were 24%, 14%, 27%, and 8%, respectively. Resistance 
rates of Pseudomonas aeruginosa to fl uoroquinolone, ceftazidime, imipenem, and amikacin were 33%, 20%, 22%, and 
16%, respectively, whereas those of Acinetobacter spp. resistance were 71%, 66%, 64, and 51%, respectively. The prevalence 
of oxyimino-cephalosporin-resistant E. coli and K. pneumoniae, carbapenem-resistant Acinetobacter spp. and P. aeruginosa, 
MRSA, and VR-EFM among ICU isolates was higher than those among non-ICU isolates. Extended-spectrum β-lactamase-
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Introduction
Over recent years, the increasing prevalence of antimicrobial-
resistant bacteria has become a serious problem worldwide. 
Bacterial surveillance previously conducted in Korea indicated 
a high prevalence of methicillin-resistant Staphylococcus aure-
us (MRSA), penicillin G-resistant Streptococcus pneumoniae, 
vancomycin-resistant Enterococcus faecium (VR-EFM), and ex-
tended cephalosporin-resistant Enterobacteriaceae. The recent 
increase in multidrug-resistant (MDR) Acinetobacter spp. and 
Pseudomonas aeruginosa, and carbapenem-resistant Klebsiel-
la pneumoniae is of great concern in many countries. The prev-
alence of resistant bacteria varies substantially from country to 
country, and even from hospital to hospital, as it is influenced 
significantly by antimicrobial use and the degree of success of 
efforts to control the spread of resistant bacteria.
Surveillance of antimicrobial resistance provides essential 
data that increases our understanding of the epidemiology of 
antimicrobial resistance and aids in optimizing empirical 
management regimens, driving pharmaceutical companies to 
develop new antimicrobial agents, and adopting better mea-
sures for controlling antimicrobial resistance. Since 1997, the 
Korean Nationwide Surveillance of Antimicrobial Resistance 
(KONSAR) program has conducted passive surveillance via 
the analysis of data from tests conducted by participating lab-
oratories [1]. A study in 2009 showed a continued high preva-
lence of MRSA, third-generation cephalosporin-resistant K. 
pneumoniae, and fluoroquinolone-resistant Escherichia coli, 
P. aeruginosa, and Acinetobacter spp. There was a minor in-
crease in the prevalence of imipenem-resistant P. aeruginosa, 
but there was a dramatic increase in the prevalence of imipe-
nem-resistant Acinetobacter spp. MDR microorganisms were 
much more common among isolates from intensive care units 
(ICUs) than those from non-ICUs.
The aim of this study was to analyze the antimicrobial resis-
tance patterns of clinically significant bacteria isolated in 2011 
in Korea. Resistance rates were compared between isolates 
from ICUs and those from non-ICUs. Resistance patterns of 
isolates derived from secondary care hospitals and primary 
care clinics that did not have clinical microbiology laborato-
ries were provided by two commercial laboratories. Resis-
tance patterns of isolates derived from tertiary care hospitals 
were also analyzed. The prevalence of colistin resistance was 
also assessed, due to the increasing prevalence of MDR Aci-
netobacter spp. and P. aeruginosa.
Materials and Methods
Antimicrobial susceptibility test data generated in 2011 by 
KONSAR-participating laboratories were collected from 32 
hospitals and two commercial laboratories, which processed 
specimens at the request of secondary care hospitals and pri-
mary care clinics. Data from hospitals with poor quality per-
formance, such as those indicating susceptibility to intrinsi-
cally resistant antimicrobials, were excluded. Resistance 
patterns of clinically significant microorganisms isolated from 
ICU patients were compared to organisms isolated from non-
ICU patients using data from 20 hospitals.
Questionnaire responses revealed that one laboratory tested 
the susceptibility of E. coli (representing Gram-negative bacil-
li) and S. aureus (representing gram-positive cocci) using 
Clinical and Laboratory Standards Institute (CLSI) disk diffu-
sion [2], while 25 laboratories used commercial broth micro-
dilution. One laboratory used both methods. Cefotaxime and 
ceftazidime susceptibility was interpreted using previous CLSI 
[2] breakpoints. For S. pneumoniae, the oxacillin disk method 
with meningitis breakpoint was used to screen penicillin G-
producing E. coli and K. pneumoniae, imipenem-resistant P. aeruginosa, and VR-EFM were more prevalent among isolates from 
commercial laboratories than those from hospitals. Resistance rates of K. pneumoniae to ceftazidime and amikacin decreased from 
32% and 24% in 2005 to 24% and 8% in 2011, respectively. The resistance rate of P. aeruginosa to amikacin decreased from 22% 
in 2005 to 16% in 2011. The proportion of imipenem-resistant Acinetobacter spp. increased from 16% in 2005 to 64% in 2011.
Conclusions: The prevalence of MRSA, penicillin G-non-susceptible S. pneumoniae, and ampicillin-resistant E. faecium among 
clinical isolates tested in laboratories remained high. Multidrug resistance was more prevalent among isolates from ICUs. The 
prevalence of ceftazidime-resistant and amikacin-resistant K. pneumoniae and amikacin-resistant P. aeruginosa decreased after 
2005, while the prevalence of imipenem-resistant Acinetobacter spp. increased.
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non-susceptible isolates [3].
The majority of laboratories used WHONET software [4] to 
analyze susceptibility data. Duplicate isolates were excluded 
from the analysis. As in the 2009 study [5], resistance rates did 
not include intermediate susceptibility and mean resistance 
rates were calculated by averaging hospital resistance rates to 
avoid the influence of high numbers of isolates from large 
hospitals. Hospitals that tested fewer than 10 isolates of an or-
ganism were excluded from the analysis to avoid bias [6, 7]. 
The statistical significance of differences between resistance 
rates was not determined in this surveillance as this has been 
a common feature of large-scale and continuous surveillance 
programs [8, 9]. 
Among the hospital laboratories that participated in the 
study, 22 modified the measured susceptibility results of cefo-
taxime/ceftriaxone, ceftazidime, cefepime, and aztreonam if the 
E. coli and K. pneumoniae isolates tested were extended-spec-
trum β-lactamase (ESBL) producers [2, 3]. We therefore com-
pared unmodified resistance rates for these antibiotics from the 
remaining five hospital laboratories with data from the previous 
KONSAR studies in order to maintain data consistency. 
Results
1. Prevalence of bacterial species
In 2011, 164,686 bacterial isolates were tested in participat-
ing hospitals and 72,119 in participating commercial labora-
tories (Table 1). The most prevalent bacterial species detected 
in hospital laboratories were as follows: E. coli (22.7%), S. au-
reus (16.6%), coagulase-negative staphylococci (CNS, 11.9%), K. 
pneumoniae (10%), and P. aeruginosa (9.1%). The most preva-
lent bacterial species detected in commercial laboratories were 
as follows: E. coli (27.3%), P. aeruginosa (12.7%), S. aureus 
(12.3%), K. pneumoniae (11.5%), and CNS (9.1%) (Table 1). The 
bacterial species most often isolated from the ICUs of 20 hospi-
tals were as follows: S. aureus (21.6%), Acinetobacter spp. 
(18.9%), CNS (12.8%), P. aeruginosa (10.7%), and K. pneumoni-
ae (10.2%) (data not shown).
2. Antimicrobial resistance of hospital isolates
Antimicrobial resistance rates among gram-positive cocci 
are shown in Table 2. The resistance rates of S. aureus were 
66% to oxacillin/cefoxitin and 59% to clindamycin. A total of 
3% of E. faecalis isolates were resistance to ampicillin and 1.2% 
to vancomycin. Among E. faecium isolates, 92% were resistant 
to ampicillin and 23% to vancomycin. Of 2,750 S. pneumoniae 
isolates, 70% were resistant to penicillin G.
The antimicrobial resistance rates of isolated Gram-negative 
bacilli are shown in Table 3. Of the E. coli isolates, 68% were 
resistant to ampicillin, 8% to cefoxitin, 6% to piperacillin-tazo-
bactam, 1% to amikacin, 36% to ciprofloxacin/levofloxacin, 
and 35% to trimethoprim-sulfamethoxazole. Of E. coli isolates 
from the five hospitals where provide unmodified resistance 
Table 1. Number, proportion, and rank by frequency of clinically important bacteria isolated in 2011
Bacteria
Hospitals Commercial laboratories
No. (%) of isolates Rank No. (%) of isolates Rank 
Escherichia coli 37,308 (22.7)   1 19,654 (27.3)   1
Klebsiella pneumoniae 16,404 (10)   4 8,264 (11.5)   4
Enterobacter cloacae 4,499 (2.7)   9 1,573 (2.2) 11
Serratia marcescens 2,577 (1.6) 12 2,736 (3.8)   8
Stenotrophomonas maltophilia 3,393 (2.1) 10 1,813 (2.5) 10
Acinetobacter spp. 11,671 (7.1)   7 5,431 (7.5)   6
Pseudomonas aeruginosa 15,032 (9.1)   5 9,127 (12.7)   2
Haemophilus influenzae 976 (0.6) 13 23 (0.03) 14
Non−typhoidal Salmonella 560 (0.3) 14 99 (0.1) 13
Staphylococcus aureus 27,314 (16.6)   2 8,841 (12.3)   3
Coagulase−negative staphylococci 19,574 (11.9)   3 6,594 (9.1)   5
Enterococcus faecalis 12,916 (7.8)   6 5,394 (7.5)   7
Enterococcus faecium 9,757 (5.9)   8 1,984 (2.8)   9
Streptococcus pneumoniae 2,750 (1.7) 11 586 (0.8) 12
Total 164,686 (100) 72,119 (100)
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rates, 17% were resistant to cefotaxime/ceftriaxone, 8% to cef-
tazidime and cefepime, and 10% to aztreonam. Of the E. coli 
isolates tested in hospitals laboratories, 20% were ESBL pro-
ducers. 
Resistance rates of K. pneumoniae were 14% to cefoxitin, 
15% to piperacillin-tazobactam, 8% to amikacin, 27% to cipro-
floxacin/levofloxacin, and 22% to trimethoprim-sulfamethox-
azole. The prevalence of ESBL-producing K. pneumoniae was 
32%. Table 3 shows that resistance rates of K. pneumoniae 
isolates sampled from five hospitals that adopted the 2010 
CLSI guidelines were 24% to cefotaxime/ceftriaxone and cef-
tazidime, 17% to cefepime, and 25% to aztreonam.
Resistance rates of Enterobacter cloacae and Serratia marc-
escens were 31% and 14% to ceftazidime, respectively, 7% and 
8% to cefepime, respectively, 3% and 9% to amikacin, respec-
tively, and 8% and 14% to fluoroquinolones (ciprofloxacin or 
levofloxacin), respectively. The resistance rates of Acineto-
bacter spp. were 55% to ampicillin-sulbactam, 66% to ce-
fepime, 64% to imipenem, 51% to amikacin, and 71% to cipro-
floxacin/levofloxacin. The resistance rates of P. aeruginosa 
were 20% to ceftazidime, 22% to imipenem, 16% to amikacin, 
and 33% to ciprofloxacin/levofloxacin.
The resistance rates of 560 non-typhoidal Salmonella iso-
lates were 36% to ampicillin, 1% to ciprofloxacin/levofloxacin, 
and 2.6% to trimethoprim-sulfamethoxazole (data not shown). 
Among 928 H. influenzae isolates, 53% were resistant to ampi-
cillin. The resistance rates of Stenotrophomonas maltophilia 
were 42% to ceftazidime, 8% to ciprofloxacin/levofloxacin, 
and 8% to trimethoprim-sulfamethoxazole.
3.  Antimicrobial resistance rates of commercial 
laboratory-tested isolates
The resistance rates of S. aureus isolates tested in commer-
cial laboratories were 66% to oxacillin/cefoxitin and 56% to 
clindamycin (Table 2). The resistance rates of E. faecium were 
90% to ampicillin and 27% to vancomycin. Of 586 S. pneu-
moniae isolates tested in commercial laboratories, 64% were 
resistant to penicillin G according to the CLSI meningitis 
breakpoints.
Resistance rates of E. coli were 70% to ampicillin, 10% to 
cefoxitin, 8% to piperacillin-tazobactam, 2% to amikacin, and 
44% to ciprofloxacin/levofloxacin (Table 3). Of the E. coli 
strains isolated in commercial laboratories, 28% were ESBL 
producers.
Table 2. Antimicrobial resistance rates (number tested) of clinically important Gram−positive cocci isolated at hospitals and tested at commercial labo-
ratories in 2011
Antimicrobial 
agents
Staphylococcus 
aureus  a
Coagulase−nega-
tive staphylococci a
Enterococcus 
faecalis
Enterococcus 
faecium
Streptococcus 
pneumoniae
HOSP
(27,314)
CM
(8,841)
HOSP
(19,574)
CM
(6,594)
HOSP
(12,916)
CM
(5,394)
HOSP
(9,757)
CM
(1,984)
HOSP
(2,750)
CM
(586)
Penicillin/AMPa 96 96 93 93   3 NT 92 90 70b 64c
Oxacillin/FOX 66 66 73 70 − − − − 85c NT
Gentamicin 47 49 40 28 − − − − − −
Ciprofloxacin/LEV 51 50 40 32 28 32 92 89 6 10
Clindamycin 59 56 38 33 − − − − 66 NT
Erythromycin 60 58 56 55 68 75 88 90 74 78
T rimethoprim− 
sulfamethoxazole
  2 NT 28 NT − − − − 53 NT
Tetracycline 51 50 28 26 85 89 33 30 73 77
Teicoplanin 0.01   0 0.15       1.4       1.2       0.8 18 24 − −
Vancomycin   0   0 0.01   0       1.2       1.3 23 27 − −
Q uinupristin− 
dalfopristin
0.04 0.2 0.2       0.2 − − 1.2 1.5 − −
Linezolid 0.03 0.5 0.06       0.5       0.5       0.9 0.4 1.2 − −
HOSP, hospital laboratory; CM, commercial laboratory; AMP, ampicillin; FOX, cefoxitin; LEV, levofloxacin; NT, not tested; −, not applicable.
a Penicillin G resistance for Staphylococcus  spp., and ampicillin resistance for Enterococcus  spp.
b Penicillin G resistance by MIC determination with meningitis breakpoint.
c Oxacillin disk screening to predict penicillin G resistance with meningitis breakpoint [3].
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The resistance rates of K. pneumoniae were 52% to cephalo-
thin/cefazolin, 25% to cefoxitin, 32% to piperacillin-tazobac-
tam, 20% to amikacin, and 35% to ciprofloxacin/levofloxacin 
(Table 3). Of K. pneumoniae isolates, 46% were ESBL-positive. 
The resistance rates of E. cloacae and S. marcescens were 19% 
and 8% to ceftazidime, respectively, 5% and 6% to cefepime, 
respectively, 4% and 13% to amikacin, respectively, and 12% 
and 10% to ciprofloxacin/levofloxacin, respectively.
The resistance rates of Acinetobacter spp. were 46% to ampi-
cillin-sulbactam, 61% to cefepime, 59% to imipenem, 13% to 
amikacin, and 70% to ciprofloxacin/levofloxacin. The resistance 
rates of P. aeruginosa were 28% to ceftazidime, 38% to imipen-
em, 27% to amikacin, and 52% to ciprofloxacin/levofloxacin.
The resistance rates of 99 non-typhoidal Salmonella isolates 
tested in commercial laboratories were 45% to ampicillin and 
0% to ciprofloxacin/levofloxacin (data not shown). Among 23 
H. influenzae isolates, 48% were resistant to ampicillin. The 
resistance rates of S. maltophilia were 22% to ceftazidime and 
15% to ciprofloxacin/levofloxacin.
4.  Resistance rates of isolates from ICU and  
non-ICU patients
The prevalences of antimicrobial-resistant microorganisms 
isolated from ICU patients vs. non-ICU patients from 20 hospi-
tals are shown in Figure 1. Prevalences of cefotaxime-resistant 
E. coli, ceftazidime-resistant K. pneumoniae, imipenem-resis-
tant Acinetobacter spp., imipenem-resistant P. aeruginosa, oxa-
cillin-resistant S. aureus, and VR-EFM from ICU patients was 
Table 3. Antimicrobial resistance rates (number tested) of clinically important Gram−negative bacilli isolated at hospitals and tested at commercial 
laboratories in 2011a
Antimicrobial 
agents
Escherichia 
coli
Klebsiella 
pneumoniae
Enterobacter 
cloacae
Serratia 
marcescens
Acinetbacter spp.
Pseudomonas 
aeruginosa
HOSP
(37,308)
CM
(19,654)
HOSP
(16,404)
CM
(8,264)
HOSP
(4,499)
CML
(1,573)
HOSP
(2,577)
CM
(2,736)
HOSP
(11,671)
CM
(5,431)
HOSP
(15,032)
CM
(9,127)
Ampicillin 68 70 − − − − − − − − − −
Ampicillin−SUL 34 NT 37 NT − − − − 55 46 − −
Cephalothin/CFZ 31 36 38   52 − − − − − − − −
Cefotaxime/CRO 17 − 24 − 33 11 24 25 70 70 80 98
Ceftazidime   8 − 24 − 31 19 14   8 66 68 20 28
Cefepime   8 − 17 −   7   5   8   6 66 61 20 29
Aztreonam 10 − 25 − 29 14 17 20 80 76 21 28
Cefoxitin   8 10 14   25 − − − − − − − −
Piperacillin 65 67 99 100 38 33 27 39 67 71 29 42
Piperacillin−TAZ   6   8  15   32 24 15 11 10 66 69 25 40
Imipenem 0.1 0.01 0.4 0.3 0.3 0.3   2 0.6 64 59 22 38
Meropenem 0.04 0.01 0.4 0.3 0.1 0.2   1 0.3 63 58 19 28
Amikacin   1   2 8   20   3   4   9 13 51 13 16 27
Gentamicin 27 32 17   27  11 10 17 29 67 65 25 36
Tobramycin 12 16 22   39 16 20 23 39 57 55 22 33
Ciprofloxacin/LEV 36 44 27   35   8 12 14 10 71 70 33 52
T rimethoprim- 
sulfamethoxazole
35 NT 22 NT 19 NT 11 NT 63 NT − −
Tetracycline 43 NT 18 NT 12 NT 56 NT 40 NT − −
Minocycline − − − − − − − −   3   3 − −
Colistin − − − − − − − − 1.9 2.6 1.8   5
HOSP, hospital laboratory; CM, commercial laboratory.; SUL, sulbactam; CFZ, cefazolin; CRO, ceftriaxone; TAZ, tazobactam; LEV, levofloxacin; NT, not tested; −, not ap-
plicable.
a Number of isolates tested are shown in parentheses.
Additional data: ESBL−positive rates for E. coli : 20% for hospitals and 28% for commercial laboratory isolates; ESBL−positive rates for K. pneumoniae : 32% for hospitals 
and 46% for commercial laboratory isolates.
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almost two-fold higher than those from non-ICU patients. 
5.  Resistance rates of isolates sampled from both 
hospital and commercial laboratories
Figure 2 shows the resistance rates of bacterial isolates test-
ed in both hospital and commercial laboratories. ESBL-pro-
ducing E. coli, ESBL-producing K. pneumoniae, imipenem-
resistant P. aeruginosa, and VR-EFM were more prevalent 
among isolates tested by commercial laboratories than those 
tested by hospitals. However, imipenem-resistant Acineto-
bacter spp. was more prevalent in hospital isolates than in 
commercial laboratory isolates. The proportion of S. aureus 
isolates that were oxacillin-resistant was 66% in both hospital 
and commercial laboratories.
6. Trends in resistance
Trends in antimicrobial resistance patterns in hospital iso-
lates were compared between 2005 and 2011 as, since 2005, 
duplicate isolates have been excluded in resistance rate calcu-
lations. MRSA, penicillin G-nonsusceptible S. pneumoniae, 
and ampicillin-resistant E. faecium remained highly prevalent 
among the 2011 samples (Fig. 3). The proportion of VR-EFM 
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gradually increased from 20% in 2005 to 29% in 2009, but de-
creased to 23% in 2011. 
Of the Gram-negative bacilli, K. pneumoniae resistance to 
ceftazidime decreased from 32% in 2005 to 24% in 2011, resis-
tance to cefoxitin decreased from 24% in 2005 to 14% in 2011 
(Fig. 4), and resistance to amikacin decreased from 24% in 
2005 to 8% in 2011.
From 2005 to 2011, resistance rates of Acinetobacter spp. to 
fluoroquinolone increased from 51% to 71%, to amikacin in-
creased from 43% to 51%, and to ceftazidime increased from 
56% to 66% (Fig. 5). The proportion of imipenem-resistant iso-
lates steadily increased from 16% in 2005 to 22% in 2007, and 
to 64% in 2011.
The resistance rates of P. aeruginosa to fluoroquinolone and 
ceftazidime were 33-39% and 19-23% in 2005-2011 (Fig. 6). 
However, the rate of amikacin resistance decreased from 22% 
in 2005 to 16% in 2011 and the rate of imipenem resistance 
slightly increased from 19% in 2005 to 26% in 2009 and then 
decreased to 22% in 2011 among P. aeruginosa isolates.
Discussion
The prevalence of antibiotic-resistant bacteria varies signifi-
cantly by time, country, and patient population. Antimicrobial 
resistance surveillance studies are important for monitoring 
the levels of endemic or emerging resistance. This KONSAR 
study report showed that the majority of hospital laboratories 
used commercial broth microdilution methods for E. coli 
(Gram-negative) and S. aureus (Gram positive) susceptibility 
testing. 
In terms of laboratory analysis of susceptibility data, the 
CLSI [10] recommends including only the first isolate in cases 
of multiple isolates from a single patient, in order to effectively 
guide clinicians in the empirical selection of appropriate anti-
microbial agents. In this study, we excluded duplicate isolates. 
However, excluding duplicate isolates may have the effect of 
underestimating the resistance rates of some organisms to 
certain antimicrobial agents, especially when this analysis is 
conducted only once a year. To detect the development of re-
sistance during antimicrobial therapy, the CLSI [3] recom-
mends susceptibility testing to third-generation cephalospo-
rins in Enterobacter, Citrobacter, and Serratia spp. isolates 
obtained three to four days after initial isolation. P. aeruginosa 
should be tested for susceptibility to all antimicrobial agents; 
and staphylococci should be tested for susceptibility to fluoro-
quinolones. 
Although the commercial laboratory isolates included bac-
terial strains originating from hospitals, we tried to separate 
and compare the hospital and commercial laboratory isolates 
in order to follow up trends in each MDR microorganisms to 
make comparisons with previous KONSAR studies. In 2011, E. 
coli, S. aureus, CNS, K. pneumoniae, and P. aeruginosa were 
the five most prevalent organisms isolated by hospitals (Table 
1). Compared with 2009 data, the relative prevalences of K. 
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pneumoniae and P. aeruginosa changed. In 2009, K. pneu-
moniae was the fifth most prevalent and P. aeruginosa the 
fourth most prevalent bacterial species isolated. Among the 
commercial laboratory isolates, E. coli, P. aeruginosa, S. aure-
us, K. pneumoniae and CNS (in order of decreasing preva-
lence) were the most commonly isolated. E. faecalis was the 
seventh most common in 2011 but fifth in 2009. Among ICU 
isolates, S. aureus, Acinetobacter spp., CNS, P. aeruginosa, and 
K. pneumoniae were the five most commonly isolated micro-
organisms. EARSS/EARS-Net data from 2011 (www.ecdc.eu-
ropa.eu) showed that E. coli was the most prevalent species, 
accounting for 73% (344,700 of 471,596) of bacterial isolates, 
followed by K. pneumoniae (16%, 74,985 isolates) and P. ae-
ruginosa (11%, 51,911 isolates). These data are similar to our 
results.
Antimicrobial pressure is much higher on ICUs than on gen-
eral wards [11, 12]. Analysis of ICU data from 20 hospitals in 
this study showed that extended-spectrum cephalosporin-re-
sistant E. coli and K. pneumoniae, imipenem-resistant Aci-
netobacter spp. and P. aeruginosa, oxacillin/cefoxitin-resistant 
S. aureus, and VR-EFM were more prevalent among ICU iso-
lates than non-ICU isolates (Fig. 1). A comparison of resis-
tance in ICU isolates analyzed in this study with data from an 
international study showed that rates of MRSA and piperacil-
lin-resistant P. aeruginosa were similar to rates from regions 
outside the United States: 84% and 84.1% for MRSA, and 84% 
and 78% for piperacillin-resistant P. aeruginosa [13].
In Korea, hospital-associated MRSA is a serious problem. In 
this study, the prevalence of MRSA was 66% in both hospital- 
and commercial laboratory-tested isolates (Table 2, Fig. 2). Of 
the invasive S. aureus isolates reported in the 2011 EARS-Net 
data, 54.6% of 1,307 S. aureus isolates from Portugal, 20.1% of 
4,716 isolates from France, and 13.6% of 3,408 isolates from 
the United Kingdom were non-susceptible to oxacillin (www.
ecdc.europa.eu). 
Vancomycin-resistant enterococci are also important Gram-
positive nosocomial pathogens (Table 2). In this study, vanco-
mycin resistance was 1.2% for hospital-isolated E. faecalis and 
23% for hospital-isolated E. faecium. In 2011, the resistance 
rates of vancomycin in Denmark, Finland, and France were 
found to be ≤ 1%, while the rates in Germany and Greece were 
11% and 23%, respectively (www.ecdc.europa.eu). The Euro-
pean report also showed that resistance rates varied by hospi-
tal, even within countries.
Commercial laboratory-tested E. faecium isolates showed 
slightly higher resistance rates to teicoplanin and vancomycin 
than isolates tested in hospital laboratories (Table 2, Fig. 1). 
These data suggest that the prevalence of nosocomial VR-EFM 
infection was common in participating secondary care hospi-
tals and primary care clinics.
Interestingly, the resistance rates of E. coli and K. pneu-
moniae to cephalothin/cefazolin, piperacillin-tazobactam, 
amikacin, and ciprofloxacin/levofloxacin were lower among 
hospital isolates than among commercial laboratory isolates 
(Table 3). In 2011, the CLSI [3] lowered the resistance break-
points of cefotaxime to ≥ 4 μg/mL, ceftazidime to ≥ 16 μg/mL, 
and aztreonam to ≥ 16 μg/mL. The CLSI also eliminated the 
requirement for ESBL testing of E. coli, K. pneumoniae spp., 
and P. mirabilis. In this study, only five hospitals followed 
these guidelines, with the remaining hospitals testing for ESBL 
production. The rates of ESBL-positivity were slightly lower for 
hospital-isolated E. coli and K. pneumoniae than for commer-
cial laboratory-tested isolates (Table 3, Fig. 2). The resistance 
rates of hospital-isolated E. cloacae and S. marcescens to cefo-
taxime, ceftazidime, and piperacillin-tazobactam were higher 
compared to those of isolates tested in commercial laborato-
ries.
Currently, resistance to carbapenems is the most worrying 
type of antimicrobial resistance. Carbapenem resistance 
among Acinetobacter spp. was higher than that among P. ae-
ruginosa (Table 3, Fig. 5, Fig. 6). Resistance to imipenem was 
higher in hospital-tested Acinetobacter spp. isolates than in 
commercial laboratory-tested isolates (Table 3, Fig. 2). In this 
study, 22% of hospital-isolated P. aeruginosa were resistant to 
imipenem. This is much higher than the 5.5% observed in 
Denmark and 4.6% in the Netherlands, but lower than the 
66.7% found in Romania (www.ecdc.europa.eu). The imipen-
em resistance rate of P. aeruginosa isolates tested in hospital 
laboratories was lower than for isolates tested in commercial 
laboratories. 
Ampicillin resistance among hospital-isolated non-typhoi-
dal Salmonella spp. substantially increased from 20% in 2009 
[14] to 36% in 2011 (data not shown). Resistance rates differed 
significantly depending on the hospital, ranging from 3% to 
83%. These data indicate the presence of local outbreaks in 
some settings. In this study, 53% of hospital isolates and 48% 
of commercial laboratory isolates of H. influenzae were resis-
tant to ampicillin, suggesting stability, since previous data 
were 58.5% in 2005 and 2006 [15].
The prevalence of imipenem-resistant P. aeruginosa de-
creased slightly between 2009 and 2011, while imipenem re-
sistance in Acinetobacter spp. increased (Fig. 5 and 6). Ac-
cording to previous KONSAR studies, imipenem resistance 
rates among P. aeruginosa isolates were 19% in 2005, 26% in 
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2009, and 22% in 2011. Among Acinetobacter spp., resistance 
rates were 16% in 2005, 51% in 2009, and 64% in 2011. The 
drastic increase in the prevalence of imipenem-resistant Aci-
netobacter spp. is mostly due to OXA-type carbapenemase 
production. Almost all carbapenem-resistant A. baumannii 
carried blaOXA-23-like or ISAba1-activated blaOXA-51-like genes, 
while most non-baumannii Acinetobacter carried metallo-β-
lactamase genes [16].
Colistin-resistant A. baumannii isolates have previously 
been detected in Korea [17]. While colistin-resistance rates in 
Acinetobacter spp. isolated in Korea vary substantially be-
tween studies [18], colistin susceptibility must be included in 
surveillance studies because colistin is the last resort for treat-
ment of MDR Acinetobacter spp. infections [19]. In this study, 
the colistin resistance rate in hospital-isolated Acinetobacter 
spp. was less than 2%, which was significantly lower than pre-
vious reports of 30.6% [17] and 9.1% [20].
The emergence of antibiotic resistance is inevitable and 
therefore efforts to decrease the impact of resistance and pro-
long the effectiveness of available agents are required. For this 
reason, surveillance of antimicrobial resistance must contin-
ue, in order to determine trends in emerging resistant organ-
isms in Korea such as OXA-48 and OXA-232-producing Gram-
negative bacilli [21, 22].
In conclusion, this KONSAR study of data collected in 2011 
showed that among bacteria isolated in hospital laboratories, 
the prevalence of ciprofloxacin/levofloxacin resistance and 
amikacin resistance in Acinetobacter spp. increased; imipenem 
resistance also increased substantially in this microorganism. 
The prevalence of carbapenem-resistant, amikacin-resistant, 
ceftazidime-resistant, and ciprofloxacin/levofloxacin-resistant 
P. aeruginosa, and ceftazidime-resistant, ciprofloxacin/levo-
floxacin-resistant, amikacin-resistant, and cefoxitin-resistant 
K. pneumoniae decreased compared with data from 2009. 
MDR organisms were much more common among isolates 
taken from ICUs.
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